Abstract: Objective: The purpose of this study was to investigate the mechanism of fasudil on no-reflow patients' coronary endothelial inflammation through observation of the impact of fasudil on circulating blood endothelial microparticles (EMPs) and soluble intercelluar adhesion molecule-1(sICAM-1) level of patients with coronary no-reflow. Method: The 90 ACS patients treated with PCI were selected. The 60 patients of them were no-reflow after PCI, and randomly divided into two groups,Group A consists of 30 patients with 5 mg fasudil were injected into coronary artery,Group B consists of 30 patients with 500 μg tirofiban were injected into coronary artery. Remained 30 patients of 90 without the occurrence of no-reflow was named group C (control group). Venous blood of patients in the three groups was collected when they were on admission, immediately after PCI and 24 h after PCI respectively. Plasma EMPs levels and serum sICAM-1 levels were mensurated. Result: EMPs and sICAM-1 levels of three groups have no difference on admission (P>0.05); EMPs and sICAM-1 levels of group A and group B immediately after PCI were significantly higher than those of group C(all P<0.05),EMPs and sICAM-1 levels of group A and group B 24 h after PCI were significantly lower than those of group C(all P<0.05),The EMPs level was highly positively correlated with sICAM-1 level (0.7<r< 1, P<0.05).The incidence of low blood pressure between group A and group B had no difference,and the incidence of bleeding and thrombocytopenia of group A was lower than those of group B. Conclusion: Fasudil could significantly reduce the plasma EMPs and serum sICAM-1 levels in patients with no-reflow after PCI. Fasudil can reduces inflammation and is a safe way to improve the no-reflow.